APPLICATION
ANDA205407
TYPE
ANDA
ORIGINAL APPROVAL
2015-12-23
LATEST ACTION
2024-11-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 40MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 10MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 20MG BASE · TABLET · ORAL
Approval history
2024-11-14Labeling · Supplement 9 · standardAP
2024-11-14Labeling · Supplement 1 · standardAP
2024-11-14Labeling · Supplement 6 · standardAP
2015-12-23UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.